Active Ingredient(s): Fam-trastuzumab Deruxtecan-nxki
FDA Approved: * December 20, 2019
Pharm Company: * DAIICHI SANKYO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Enhertu Overview

Trastuzumab deruxtecan, sold under the brand name Enhertu, is a monoclonal antibody medication used for the treatment of breast cancer or for the treatment of gastric or gastroesophageal adenocarcinoma.[4][5] Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan).[6][4...

Read more Enhertu Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Trastuzumab_deruxtecan

Recent Enhertu Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fam-trastuzumab Deruxtecan-nxki
  • Injection: 100mg, 150mg, 420mg, 420mg/vial, 440mg, 600mg + 10000units
  • Vial: 100mg, 150mg, 160mg, 21mg/ml, 420mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Enhertu: (1 result)

Sorted by National Drug Code
  • 65597-406 Enhertu 100 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Daiichi Sankyo Inc.

Other drugs which contain Fam-trastuzumab Deruxtecan-nxki or a similar ingredient: (12 results)